Skip to main content
Premium Trial:

Request an Annual Quote

Merck Licenses Deltagen Gene Function Database

NEW YORK, Feb. 11—Deltagen has licensed its mammalian gene function database to Merck, the company said in a statement today.

By the terms of the deal, Merck has non-exclusive access to functional data from 750 genes and some associated intellectual property rights. 

Deltagen’s DeltaBase organizes  in vivo mammalian gene function information derived from large-scale mouse knockout studies. The database connects phenotypic information from these studies with expression profile data to clarify gene interrelationships and biochemical pathways. 

Other database subscribers include Lexicon, GlaxoSmithKline, Pfizer and Vertex.

Financial details of this deal were not disclosed. In 2000, DeltaBase charged Pfizer $15 million for a three-year subscription. 

Redwood City, Calif.-based Deltagen is publicly owned. The company also is working on a database that will use mouse knockouts to collect gene expression profiles in a range of tissues.  
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.